194 related articles for article (PubMed ID: 33009708)
1. Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network.
Ruigómez A; Brobert G; Vora P; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):229-236. PubMed ID: 33009708
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
6. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
[TBL] [Abstract][Full Text] [Related]
7. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
9. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
11. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
12. Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.
Weaver P; Ng TH; Breeden T; Edwin SB; Haan B; ; Giuliano C
Ann Pharmacother; 2022 Dec; 56(12):1315-1324. PubMed ID: 35505606
[TBL] [Abstract][Full Text] [Related]
13. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
Fung KP; Chan KH; Ng V; Tsui PT; You JHS
Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Thromb Thrombolysis; 2022 Oct; 54(3):438-448. PubMed ID: 35562510
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
19. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
